Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Polaris Observatory Collaborators,Devin Razavi-Shearer,Ivane Gamkrelidze,Calvin Pan,Jidong Jia,Thomas Berg,Richard Gray,Young-Suk Lim,Chien-Jen Chen,Ponsiano Ocama,Hailemichael Desalegn,Zaigham Abbas,Ayat Abdallah,Alessio Aghemo,Sabohat Ahmadbekova,Sang Hoon Ahn,Inka Aho,Ulus Akarca,Nasser Al Masri,Abduljaleel Alalwan,Seyed Alavian,Said Al-Busafi,Soo Aleman,Faleh Alfaleh,Abdullah Alghamdi,Waleed Al-Hamoudi,Abdulrahman Aljumah,Khalid Al-Naamani,Ahmad Al-Rifai,Yousif Alserkal,Ibrahim Altraif,Jazag Amarsanaa,Motswedi Anderson,Monique Andersson,Paige Armstrong,Tarik Asselah,Kostas Athanasakis,Oidov Baatarkhuu,Ziv Ben-Ari,Aicha Bensalem,Fernando Bessone,Mia Biondi,Abdul Rahman Bizri,Sarah Blach,Wornei Braga,Carlos Brandão-Mello,Carol Brosgart,Kimberly Brown,Robert Brown Jr,Philip Bruggmann,Maurizia Brunetto,Maria Buti,Joaquin Cabezas,Teresa Casanovas,Chungman Chae,Henry Lik Yuen Chan,Hugo Cheinquer,Pei-Jer Chen,Kent Jason Cheng,Myeong-Eun Cheon,Cheng-Hung Chien,Gourdas Choudhuri,Peer Brehm Christensen,Wan-Long Chuang,Vladimir Chulanov,Laura Cisneros,Carla Coffin,Fernando Contreras,Nicola Coppola,Markus Cornberg,Benjamin Cowie,Matthew Cramp,Antonio Craxi,Javier Crespo,Fuqiang Cui,Chris Cunningham,Olav Dalgard,Robert De Knegt,Victor De Ledinghen,Gregory Dore,Sylvia Drazilova,Ann-Sofi Duberg,Steve Egeonu,Mohammed Elbadri,Mohamed El-Kassas,Manal El-Sayed,Chris Estes,Ohad Etzion,Elmobashar Farag,Laurent Ferradini,Paulo Ferreira,Robert Flisiak,Xavier Forns,Sona Frankova,James Fung,Edward Gane,Virginia Garcia,Javier García-Samaniego,Manik Gemilyan,Jordan Genov,Liliana Gheorghe,Pierre Gholam,Robert Gish,Pouya Goleij,Magnus Gottfredsson,Jason Grebely,Michael Gschwantler,Nanelin Alice Guingane,Behzad Hajarizadeh,Saeed Hamid,Waseem Hamoudi,Aaron Harris,Irsan Hasan,Angelos Hatzakis,Margaret Hellard,Julian Hercun,Javier Hernandez,Ivana Hockicková,Yao-Chun Hsu,Ching-Chih Hu,Petr Husa,Martin Janicko,Naveed Janjua,Peter Jarcuska,Jerzy Jaroszewicz,Deian Jelev,Agita Jeruma,Asgeir Johannessen,Martin Kåberg,Kelly Kaita,Kulpash Kaliaskarova,Jia-Horng Kao,Angela Kelly-Hanku,Faryal Khamis,Aamir Khan,Omer Kheir,Ibtissam Khoudri,Loreta Kondili,Aliya Konysbekova,Pavol Kristian,Jisoo Kwon,Martin Lagging,Wim Laleman,Pietro Lampertico,Daniel Lavanchy,Pablo Lázaro,Jeffrey V Lazarus,Alice Lee,Mei-Hsuan Lee,Valentina Liakina,Boris Lukšić,Reza Malekzadeh,Abraham Malu,Rui Marinho,Maria Cássia Mendes-Correa,Shahin Merat,Berhane Redae Meshesha,Håvard Midgard,Rosmawati Mohamed,Jacques Mokhbat,Ellen Mooneyhan,Christophe Moreno,Laure Mortgat,Beat Müllhaupt,Erkin Musabaev,Gaëtan Muyldermans,Marcelo Naveira,Francesco Negro,Alexander Nersesov,Van Thi Thuy Nguyen,Qing Ning,Richard Njouom,Rénovat Ntagirabiri,Zuridin Nurmatov,Stephen Oguche,Casimir Omuemu,Janus Ong,Ohene Opare-Sem,Necati Örmeci,Mauricio Orrego,Carla Osiowy,George Papatheodoridis,Markus Peck-Radosavljevic,Mário Pessoa,Trang Pham,Richard Phillips,Nikolay Pimenov,Loreley Pincay-Rodríguez,Dijana Plaseska-Karanfilska,Cora Pop,Hossein Poustchi,Nishi Prabdial-Sing,Huma Qureshi,Alnoor Ramji,Henna Rautiainen,Kathryn Razavi-Shearer,William Remak,Sofia Ribeiro,Ezequiel Ridruejo,Cielo Ríos-Hincapié,Marcia Robalino,Lewis Roberts,Stuart Roberts,Manuel Rodríguez,Dominique Roulot,John Rwegasha,Stephen Ryder,Shakhlo Sadirova,Umar Saeed,Rifaat Safadi,Olga Sagalova,Sanaa Said,Riina Salupere,Faisal Sanai,Juan F Sanchez-Avila,Vivek Saraswat,Narina Sargsyants,Christoph Sarrazin,Gulya Sarybayeva,Ivan Schréter,Carole Seguin-Devaux,Wai-Kay Seto,Samir Shah,Ala Sharara,Mahdi Sheikh,Daniel Shouval,William Sievert,Kaarlo Simojoki,Marieta Simonova,Dong Hyun Sinn,Mark Sonderup,Milan Sonneveld,C Wendy Spearman,Jan Sperl,Rudolf Stauber,Catherine Stedman,Vana Sypsa,Frank Tacke,Soek-Siam Tan,Junko Tanaka,Tammo Tergast,Norah Terrault,Alexander Thompson,Peyton Thompson,Ieva Tolmane,Krzysztof Tomasiewicz,Tak-Yin Tsang,Benjamin Uzochukwu,Berend Van Welzen,Thomas Vanwolleghem,Adriana Vince,Alexis Voeller,Yasir Waheed,Imam Waked,Jack Wallace,Cong Wang,Nina Weis,Grace Wong,Vincent Wong,Jaw-Ching Wu,Cesar Yaghi,Kakharman Yesmembetov,Terry Yip,Ayman Yosry,Ming-Lung Yu,Man-Fung Yuen,Cihan Yurdaydin,Stefan Zeuzem,Eli Zuckerman,Homie Razavi

DOI: https://doi.org/10.1016/S2468-1253(23)00197-8

Abstract:Background: The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and prophylaxis measures make such elimination feasible, even in the absence of a virological cure. We aimed to estimate the national, regional, and global prevalence of HBV in the general population and among children aged 5 years and younger, as well as the rates of diagnosis, treatment, prophylaxis, and the future burden globally. Methods: In this modelling study, we used a Delphi process with data from literature reviews and interviews with country experts to quantify the prevalence, diagnosis, treatment, and prevention measures for HBV infection. The PRoGReSs Model, a dynamic Markov model, was used to estimate the country, regional, and global prevalence of HBV infection in 2022, and the effects of treatment and prevention on disease burden. The future incidence of morbidity and mortality in the absence of additional interventions was also estimated at the global level. Findings: We developed models for 170 countries which resulted in an estimated global prevalence of HBV infection in 2022 of 3·2% (95% uncertainty interval 2·7-4·0), corresponding to 257·5 million (216·6-316·4) individuals positive for HBsAg. Of these individuals, 36·0 million were diagnosed, and only 6·8 million of the estimated 83·3 million eligible for treatment were on treatment. The prevalence among children aged 5 years or younger was estimated to be 0·7% (0·6-1·0), corresponding to 5·6 million (4·5-7·8) children with HBV infection. Based on the most recent data, 85% of infants received three-dose HBV vaccination before 1 year of age, 46% had received a timely birth dose of vaccine, and 14% received hepatitis B immunoglobulin along with the full vaccination regimen. 3% of mothers with a high HBV viral load received antiviral treatment to reduce mother-to-child transmission. Interpretation: As 2030 approaches, the elimination targets remain out of reach for many countries under the current frameworks. Although prevention measures have had the most success, there is a need to increase these efforts and to increase diagnosis and treatment to work towards the elimination goals. Funding: John C Martin Foundation, Gilead Sciences, and EndHep2030.